Illinois Elmiron Pigmentary Maculopathy injury lawyer
For years, Elmiron (pentosan polysulfate sodium) was the only FDA-approved oral medication for interstitial cystitis, a chronic bladder condition that disproportionately affects veterans. But by 2020, mounting evidence linked long-term Elmiron use to a distinctive form of retinal toxicity—pigmentary maculopathy—that can cause irreversible vision loss. As of 2026, thousands of lawsuits have been consolidated into multidistrict litigation (MDL) in the District of New Jersey, and settlement criteria have crystallized around specific medical and usage thresholds. We break down the current eligibility requirements, the science behind the claims, and what affected patients should document now.
MDL No. 3073: The New Jersey Framework for Elmiron Eye Damage Claims
The Elmiron MDL, presided over by Judge Brian R. Martinotti, has established a tiered settlement structure based on objective ophthalmologic findings. To qualify for compensation, plaintiffs must demonstrate both cumulative exposure and documented retinal damage. The court-approved criteria now require:
| Criterion | Required Evidence | Minimum Threshold (2026) |
|---|---|---|
| Duration of Use | Pharmacy records, prescription logs, or VA medication history | ≥ 5 years of continuous Elmiron use |
| Cumulative Dose | Total grams of pentosan polysulfate sodium ingested | ≥ 1,500 grams (approx. 300 mg/day for 5 years) |
| Retinal Imaging Findings | OCT, fundus autofluorescence, or fluorescein angiography showing pigmentary changes in the macula | Presence of hyper- or hypo-autofluorescent spots in a "moth-eaten" or "patchy" pattern |
| Visual Function Loss | Best-corrected visual acuity (BCVA) or visual field testing | ≥ 2 lines of Snellen chart decline OR 10 dB mean deviation on Humphrey field |
| Exclusion of Other Causes | Negative for age-related macular degeneration, pattern dystrophy, or other retinal disease | Confirmed by a retinal specialist |
These criteria are not static; in 2025, the MDL added a "short-term use" subcategory for patients who took Elmiron for 2–5 years but developed early-stage maculopathy. Those cases are evaluated on a sliding scale with lower base compensation.
VA Health Records and the Pentosan Polysulfate Sodium Registry
The Department of Veterans Affairs has been a critical battleground. Many veterans were prescribed Elmiron through VA urology clinics without adequate warning about ocular risks. In response, the VA established the Pentosan Polysulfate Sodium Registry in 2023 to track long-term users and offer baseline eye exams. However, as of early 2026, fewer than 40% of eligible veterans have enrolled. This is a problem: without registry documentation, veterans face an uphill battle proving their exposure timeline in court.
"The VA’s own data shows that between 1996 and 2020, over 100,000 veterans received at least one prescription for Elmiron. Yet the agency did not issue a safety communication about retinal risks until 2022—two years after the first major studies were published."
— Source: 1stbattalion3rdmarines.com and archived reference
For veterans, the settlement criteria now explicitly accept VA pharmacy records as primary evidence of cumulative dose. But the burden remains on the patient to obtain a comprehensive eye exam from a retinal specialist—ideally one familiar with Elmiron toxicity—and to file a claim before the statute of limitations expires in their state.
Three Critical Steps for Filing an Elmiron Maculopathy Claim in 2026
If you or a loved one used Elmiron and now experience blurred vision, difficulty reading, or trouble adjusting to dim light, here is our recommended action plan:
- Step 1: Gather all prescription records. Request your complete medication history from the VA, your pharmacy, or your urologist. This must show the start date, dosage, and total duration of Elmiron use. Do not rely on memory—pharmacies are required to keep records for at least 10 years.
- Step 2: Schedule a retinal evaluation. See a board-certified retinal specialist for a full workup, including OCT, fundus autofluorescence, and visual field testing. Ask specifically for documentation of "pigmentary maculopathy" or "pentosan polysulfate sodium-associated maculopathy" in the clinical notes.
- Step 3: Contact an attorney specializing in Elmiron litigation. The MDL has strict deadlines for filing. Many firms offer free case reviews and can verify whether your cumulative dose and retinal findings meet the 2026 settlement criteria. Do not attempt to file a claim without legal representation—the medical evidence requirements are complex.
As of mid-2026, the Elmiron MDL has settled approximately 1,200 cases, with average payouts ranging from $50,000 to $400,000 depending on the severity of vision loss. But the window is closing: the first bellwether trials are scheduled for late 2026, and judges are pushing for global resolution. If you have not yet filed, time is of the essence.